Mind Medicine (MindMed) (OTCMKTS:MMEDF) Shares Down 3% – Here’s What Happened

Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF) fell 3% during mid-day trading on Wednesday . The company traded as low as $15.6150 and last traded at $15.75. 1,595,561 shares were traded during trading, a decline of 53% from the average session volume of 3,376,665 shares. The stock had previously closed at $16.23.

Mind Medicine (MindMed) Trading Down 3.0%

The firm’s fifty day moving average price is $14.75 and its two-hundred day moving average price is $12.34.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) is a clinical-stage biotechnology company focused on developing innovative therapies derived from psychedelic compounds to address mental health disorders and addiction. The company’s research pipeline includes programs based on LSD, psilocybin and 18-methoxycoronaridine (18-MC), targeting conditions such as anxiety disorders, attention-deficit/hyperactivity disorder (ADHD) and opioid dependence. MindMed seeks to build a portfolio of drug candidates that combine pharmacological efficacy with optimized dosing regimens and delivery methods.

Founded in 2019 and headquartered in New York City, MindMed operates research facilities in North America and Europe, collaborating with academic institutions and medical centers to advance its clinical trials.